NASDAQ
06.11.26 | 21:59
0,823 US-Dollar
+0,41 % +0,003
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | TELA Bio, Inc.: TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| 27.10. | TELA Bio, Inc.: TELA Bio to Announce Third Quarter 2026 Financial Results | 2 | GlobeNewswire (USA) | ||
| 06.10. | TELA Bio, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 05.10. | TELA Bio Says FDA Grants 510(k) Clearance For Liora Monofilament Scaffold Product | 1 | RTTNews | ||
| 05.10. | TELA Bio, Inc.: TELA Bio Announces 510(k) Clearance for Liora Monofilament Scaffold for Soft Tissue Reinforcement | 191 | GlobeNewswire (Europe) | MALVERN, Pa., Oct. 05, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio" or the "Company"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction... ► Artikel lesen | |
| 29.09. | TELA Bio, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 18.09. | TELA Bio, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 31.08. | TELA Bio COO/CFO Roberto Cuca steps down | 3 | Seeking Alpha | ||
| TELA BIO Aktie jetzt für 0€ handeln | |||||
| 31.08. | TELA Bio cuts 20% of workforce to reduce costs by $17M annually | 3 | Investing.com | ||
| 31.08. | TELA Bio, Inc.: TELA Bio Announces COO / CFO Transition and Strategic Cost Reduction Initiative | 361 | GlobeNewswire (Europe) | MALVERN, Pa., Aug. 31, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio" or the "Company"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction... ► Artikel lesen | |
| 31.08. | TELA Bio, Inc. - 8-K, Current Report | 4 | SEC Filings | ||
| 11.08. | TELA Bio, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 3 | SEC Filings | ||
| 11.08. | TELA Bio, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 11.08. | Tela Bio outlines 9- to 12-month sales ramp while withdrawing full-year revenue guidance | 1 | Seeking Alpha | ||
| 10.08. | TELA Bio GAAP EPS of -$0.20 misses by $0.03, revenue of $19.3M misses by $0.71M | 1 | Seeking Alpha | ||
| 04.08. | TELA Bio, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings | ||
| 04.08. | TELA Bio names Heather Getz as CEO and Director | 1 | Seeking Alpha | ||
| 04.08. | TELA Bio Names Heather Getz CEO | 2 | RTTNews | ||
| 04.08. | TELA Bio appoints Heather Getz as chief executive officer | 1 | Investing.com | ||
| 04.08. | TELA Bio, Inc. - 8-K, Current Report | 1 | SEC Filings |
1 2 Weiter >>
32 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MODERNA | 227,50 | -0,11 % | Halten Zahlen den Crash auf: Apple, Palantir, AMD & Moderna: Wall Street vor explosiver Earnings-Woche! | © Foto: Richard Drew/AP/dpaDiese in den kommenden Tagen (KW45) anstehenden US-Quartalszahlen müssen Anlegerinnen und Anleger kennen: Herausforderungen, Erwartungen und die aktuell eingepreisten Kursreaktionen... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 15,960 | -0,37 % | SRPT Q3 Earnings Miss Estimates, Stock Down as Elevidys Sales Decline | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 2,070 | +2,22 % | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. - 10-Q, Quarterly Report | ||
| MYRIAD GENETICS | 5,300 | 0,00 % | MYRIAD GENETICS INC - 10-Q, Quarterly Report | ||
| PHIO PHARMACEUTICALS | 0,789 | -1,54 % | Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Announces Invitation for Oral Presentation at 41st Annual SITC Meeting (Society for Immunotherapy of Cancer) | INTASYL siRNA - Redefining the Treatment Paradigm for Cutaneous Squamous Cell CarcinomaKing of Prussia, Pennsylvania--(Newsfile Corp. - November 6, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO)... ► Artikel lesen | |
| AGIOS | 26,200 | 0,00 % | Truist senkt Kursziel für Agios Pharmaceuticals wegen Bedenken zum Sichelzellprogramm | ||
| VIR BIOTECHNOLOGY | 12,200 | -0,08 % | Vir Biotechnology, Inc.: Vir Biotechnology to Participate in the Jefferies 2026 London Healthcare Conference | Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that Marianne De Backer, M.Sc., Ph.D., MBA, President and Chief Executive Officer, will present at the Jefferies 2026 London Healthcare Conference... ► Artikel lesen | |
| ENLIVEX | 1,240 | +8,77 % | Enlivex meldet positive 12-Monats-Daten aus Phase-IIa-Studie zu Kniearthrose | ||
| BOLT BIOTHERAPEUTICS | 6,510 | -0,46 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 02.10.2026 -3- | The following instruments on Boerse Frankfurt do have their last trading day on 02.10.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 02.10.2026ISIN NameKYG200801002 CBAK... ► Artikel lesen | |
| CARIBOU BIOSCIENCES | 0,442 | 0,00 % | Caribou Biosciences, Inc. - 8-K, Current Report | ||
| BIOAFFINITY TECHNOLOGIES | 2,770 | +2,03 % | bioAffinity Technologies GAAP EPS of -$5.89, revenue of $1.1M | ||
| FIRST TRACKS BIOTHERAPEUTICS | 40,850 | -5,88 % | Guggenheim raises First Tracks stock price target to $110 on celiac data | ||
| ARRIVENT BIOPHARMA | 13,650 | +0,07 % | ArriVent BioPharma, Inc.: ArriVent BioPharma Reports Second Quarter 2026 Financial Results | Topline global pivotal Phase 3 data for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC expected 2H 2026ARR-217, a CDH17 targeted ADC for gastrointestinal malignancies, advanced to... ► Artikel lesen | |
| FOGHORN THERAPEUTICS | 1,850 | -1,07 % | Foghorn Therapeutics, Inc.: Foghorn Therapeutics Provides Update on FHD-909 and Strategic Priorities | Foghorn and Lilly will not advance FHD-909; The Collaboration also will not advance the Selective SMARCA2 degrader programCompany to focus resources on wholly owned pipeline, including a Selective... ► Artikel lesen | |
| SURROZEN | 30,810 | -0,61 % | Surrozen, Inc.: Surrozen Announces FDA Clearance of IND Application for SZN-8141 for the Treatment of Diabetic Macular Edema | First patient expected to be dosed in the DUET study in the fourth quarter of 2026 Milestone triggers second closing of March 2025 private placement expected to provide approximately $95.1M in gross... ► Artikel lesen |
TELA BIO INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +0,41 % bei einem Aktienkurs von 0,823 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu TELA BIO INC finden Sie auf Wallstreet Online.